business we will become a global, values-based, r&d-driven, biopharmaceutical leader learn more research & development ecosystem for health innovation our pipeline clinical trials investigator initiated sponsored research areas of focus oncology gastroenterology rare diseases neuroscience plasma-derived...
the base offer and shares due to over-allotments. assuming full exercise of the greenshoe option, gross proceeds will amount to eur million. the proceeds from the ipo shall be used primarily to fund the pivotal phase iii study of budesolv, phase ii and phase iii studies of tacrosolv as well as the extension...